EASL2018年最新丙型肝炎治疗推荐意见.ppt

Post-liver transplantation recurrence肝移植后ＨＣＶ复发的治疗 所有肝移植患者若再感染ＨＣＶ，应考虑治疗。 移植后１年出现明显的肝纤维化或门静脉高压预示病情进展迅速及移植失败，需紧急抗病毒治疗（Ｂ２）。 肝移植后ＨＣＶ再感染者应接受IFN-free regimen, for 12 or 24 weeks，with ribavirin (A1) 无须对他克莫司和环孢霉素的剂量进行调整，with sofosbuvir-ribavirin, sofosbuvir-ledipasviror sofosbuvir-daclatasvir 然而这类患者缺乏相关安全性数据，故密切监测尤为重要（Ｂ１）。 Because of significantly increased plasma concentrations of simeprevir, the concomitant use of simeprevir and cyclosporine A is not recommended in liver transplant recipients. No simeprevir dose changes are required with tacrolimus and sirolimus, but regular monitoring of their b